INB16 is the pharmaceutical grade cell line derived from CTV-1 and, although demonstrably different, their effects on resting NK cells are identical
2023
A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome
H Arellano-Ballestero, M Sabry, MW Lowdell Cells 12 (4), 633
2022
In Vivo Generation of Memory-like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmuneTM
KH Orchard, H Ballestero, A Zubiak, C D
2020
2019
Cytotherapy. 2019 Mar;21(3):315-326. doi: 10.1016/j.jcyt.2018.11.001. Epub 2019 Mar 23.
Sabry M, Zubiak A, Hood SP, Simmonds P, Arellano-Ballestero H, Cournoyer E, Mashar M, Pockley AG, Lowdell MW. Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures. PLoS One. 2019 Jun 26;14(6):e0218674. doi: 10.1371/journal.pone.0218674
Tsirogianni M, Grigoriou E, Kapsimalli V, Dagla K, Stamouli M, Gkirkas K, Konsta E, Karagiannidou A, Gkodopoulos K, Stavroulaki G, Pappa V, Angelopoulou M, Lowdell M, Tsirigotis P. Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine. Leuk Lymphoma. 2019 Apr 5:1-7. doi: 10.1080/10428194.2019.1581935. [Epub ahead of print]
2018
Biology Blood Marrow Transplant 2018:e-pub; https://doi.org/10.1016/j.bbmt.2018.06.019
2017
Natural killer cells differentiated in vitro from cord blood CD34+ cells are more advantageous for use as an immunotherapy than peripheral blood and cord blood natural killer cells.
Domogala A, Blundell M, Thrasher A, Lowdell MW, Madrigal JA, Saudemont A. Cytotherapy. 2017 Jun;19(6):710-720. doi: 10.1016/j.jcyt.2017.03.068. Epub 2017 Apr 17.
2016
2015
Kottaridis PD, North, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S, Grace S, Lowdell MW. Two-stage priming of allogeneic Natural Killer cells for the treatment of patients with acute myeloid leukemia; a phase I trial. PLoS One; Jun 10;10(6):e0123416. doi: 10.1371
2013
Sabry M, Lowdell MW. Tumour-primed NK cells; waiting for the green light. Frontiers in Immunology; 2013: 4:1-7. doi: 10.3389/fimmu.2013
2011
Katodritou E, North J, Kottaridis P, Verrou E, Gastari V, Chadjiaggelidou C, Sivakumaran J, Jide-Banwo S, Tsirogianni M, Zervas K, Lowdell MW. Tumor-primed Natural Killer Cells from Patients with Multiple Myeloma Lyse Autologous, NK-resistant, Bone Marrow-derived Malignant Plasma Cells. Am J Hematology; 86:967-973. doi: 10.1002/ajh.22163.
2007
North J, Bakhsh I, Marden C, Pittman H, Addison E, Navarrete C, Anderson R, Lowdell MW. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence for a two-stage process in resting NK cell activation. Journal of Immunology; 178:85-94. PMID: 17182543